Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Acq. announced
Appointed director
INSITE VISION INC (INSV) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/02/2015 8-K Quarterly results
10/28/2015 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
10/28/2015 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/19/2015 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
09/30/2015 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
09/29/2015 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
09/29/2015 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
09/28/2015 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
09/28/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amended and Restated Agreement and Plan of Merger, by and among the Company, Ranbaxy and Merger Sub, as amended and restated September 28, 2015"
09/28/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/15/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/15/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/15/2015 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
09/15/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
09/15/2015 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
09/15/2015 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Agreement and Plan of Merger, by and among the Company, Ranbaxy and Merger Sub",
"Secured Note, by and between the Company and Ranbaxy",
"Security Agreement, by and between the Company and Ranbaxy",
"IP Security Agreement, by and between the Company and Ranbaxy",
"Form of Amendment, Waiver and Consent Agreement",
"InSite Vision and Sun Pharma Enter into Merger Agreement Shareholders Will Receive $0.35 per Share in Cash at Closing InSite Terminates Merger Agreement with QLT Inc."
09/15/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
09/15/2015 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
09/08/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/08/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/04/2015 425 Form 425 - Prospectuses and communications, business combinations
09/04/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal” Bidder Favorably Concludes Due Diligence on Recent BromSite ™ Patent Lawsuit"
09/04/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
09/03/2015 425 Form 425 - Prospectuses and communications, business combinations
09/03/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/03/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/03/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share from a Global Pharmaceutical Company ALAMEDA, Calif. - September 3, 2015 — InSite Vision Inc. today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite™ patent lawsuit. InSite Vision believes the lawsuit is without merit. InSite Vision is party to a merger agreement with QLT Inc. pursuant to which QLT would acquire InSite Vision in a transaction in which InSite Vision's stockholders would receive 0.078 QLT shares for each share of InSite Vision stock, subject ..."
09/03/2015 425 Form 425 - Prospectuses and communications, business combinations
09/03/2015 8-K Other Events
09/03/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
09/03/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
09/03/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/28/2015 425 Form 425 - Prospectuses and communications, business combinations
08/27/2015 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy